Dr Senan presents ADRIATIC post hoc prespecified subsets. PCI delivered before randomization. Similar durva benefits for PCI Y/N. Strong durva benefit for carbo but not cis. Strong durva benefit for BID vs OD RT. #ESMO24 ESMO - Eur. Oncology

TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: nej.md/4gg4gqv #ESMO24

Presented at #ESMO24: The monoclonal antibody ponsegromab increased weight, improved appetite, and allowed an increase in physical activity in patients with cancer who had lost more than 5% of body weight in the past 6 months. Full trial results: nej.md/3XE645a

This time last week I was talking to fellow oncologists about not conflating every clinical outcome with our self-worth Obviously we do our best for each patient but we also tend to be our own harshest critics & judge ourselves more severely in hindsight Extend yourself grace

Great panel of speakers for the Sydney event 🌟

Calling all Cancer ♋️ Care Clinicians (Medical/Nursing/Allied Health)! We need your help to improve coordination of Diet 🍇 🍱 and Exercise 🏃‍♀️ 🎾 services for Cancer Care in Australia 🇦🇺 uniofsunshinecoast.syd1.qualtrics.com/jfe/form/SV_29…

Oncology MDT’s require the presence & expertise of all key specialities to review, discuss & formulate management plans for people with cancer presented at the meetings. They’re not MDT’s if any one of these specialties are absent.

Why are the pollies so special compared to the rest of the public service? NSW staff specialists (drs) have to take the cheapest of 3 fares quoted by the contracted govt travel agents no ifs, buts or any special consideration allowed. smh.com.au/politics/feder…

Hi friend! Elmo loves you. And Elmo will remind you every day if you need him to. ❤️

Disheartening. Frustrating. Devastating. Patients unable to access immunotherapy via PBS for recurrent NSCLC due to once in a lifetime rule that is inconsistent w/ current standard of care. Communicating this to patients is hard. Medical Oncology Group of Australia (MOGA) pls keep advocating for change 🙏

Word of the day is ‘recrudescence’ (17th century): the return of something terrible after a time of reprieve.

The crew at the annual Thoracic Oncology Group of Australasia Lung Cancer Preceptorship in Brisbane. My fave meeting of the year! 👏

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy. Read the full CheckMate 8HW trial results: nej.md/4eGp1tj

🚨 YOUNG ONC WORKSHOP IS HAPPENING THIS MORNING🚨 🙌🏻 Join Zarnie Lwin OAM Mark Nalder Tim Slattery Brandon Lau for great sessions not be missed ⏰ 8am Perth 🕰️ 9am Brisbane ⏰ 10am Sydney & Melb Medical Oncology Group of Australia i luv me some chemo Dr Andrew Parsonson Liz Connolly @nicolafoneil

Great day for lung cancer care! Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! #LCSM

Come and work at Concord 👏 0.8 FTE staff specialist medical oncologist in upper & lower GI & gynae cancer available 👏 Staff Specialist Medical Oncology Crgh Apply Via Ecredential iworkfor.nsw.gov.au/job/staff-spec…

No chemotherapy appointments were cancelled in our unit due to industrial action. Nor was it ever considered. NSW government walks back claims of cancelled chemo appointments smh.com.au/national/nsw-g…

What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72

Such a well deserved standing ovation for Chris Booth and the Challenge trial. These data are quite powerful. Much stronger evidence than what we saw in plenaries today. #ASCO25

Staggered this wasn’t a plenary at #asco25 ASCO OS benefit Minimal toxicity Cost effective Generalizable What a missed opportunity! Well done to all involved 👏